# IRD catalysts: Opus Genetics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ird/catalysts

> Opus Genetics, Inc. (IRD) has 6 upcoming catalysts. The next is the Opus Genetics, Inc. topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IRD?

Opus Genetics, Inc. (IRD) has 6 upcoming catalysts. The next is the Opus Genetics, Inc. topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "•Completed enrollment and dosing of 11 participants in the high-dose Cohort 2, with topline data, including 3-month data from Cohort 2 and 6-month data for the three Cohort 1 participants with Best vitelliform macular dystrophy, expected in Q1 2027." [Calendar and source filings](https://sec-api.dev/companies/ird/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-072493, https://www.sec.gov/Archives/edgar/data/1228627/000162828026072493/ird-20261110xex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/companies/ird/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Opus Genetics, Inc. |
| Ticker | IRD (Nasdaq) |
| SEC CIK | 1228627 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ird |

## Cash runway

Cash $89.0M as of 2026-09-30; quarterly burn $14.0M; about 19.0 months of runway at that rate (XBRL company facts, accession 0001628280-26-072697).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2022 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed, positive | "We reported positive top-line data from Phase 3 trials in RM: MIRA-2 in March 2021, MIRA-3 in March 2022 and MIRA-4 in April 2022." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125040671/ny20058362x1_424b5.htm)) |
| Sep 2023 | [RYZUMVI (ryzumvi) FDA approval](https://sec-api.dev/pdufa/ryzumvi) | IRD |  | completed, approved | "In September 2023, we announced FDA approval of POS under the brand name RYZUMVI™ for the treatment of RM; for this approval we received a $10 million milestone payment under the Nyxol License Agreement." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125040671/ny20058362x1_424b5.htm)) |
| November 12, 2024 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036124046028/ef20038443_ex99-1.htm)) |
| Q1 2025 | [APX3330 topline data readout](https://sec-api.dev/pdufa/apx3330) | IRD | presbyopia completed enrollment | scheduled | "Top-line data are expected in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036124046028/ef20038443_ex99-1.htm)) |
| March 31, 2025 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for Full Year 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125011181/ef20046473_ex99-1.htm)) |
| May 15, 2025 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125019153/ef20049034_ex99-1.htm)) |
| June 26, 2025 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD | inherited retinal diseases | completed, positive | "Research Triangle Park, NC June 26, 2025 - Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced positive topline results from VEGA-3, its second pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125023732/ef20051231_ex99-1.htm)) |
| Q3 2025 | [Opus Genetics, Inc. interim data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "The pediatric cohort is expected to complete enrollment in the second quarter of 2025, with initial data from all three patients anticipated in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125019153/ef20049034_ex99-1.htm)) |
| August 13, 2025 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125030822/ef20053851_ex99-1.htm)) |
| November 12, 2025 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125041544/ef20058670_ex99-1.htm)) |
| 1H 2026 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "We are currently enrolling participants in LYNX-3, with topline results from trial expected in the first half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/ef20060643_10k.htm)) |
| 1H 2026 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "LYNX-3, the second pivotal Phase 3 trial in keratorefractive participants with visual disturbances under mesopic, low-contrast conditions (dim light disturbances), is ongoing with topline results expected in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036126008621/ef20067388_ex99-1.htm)) |
| Q1 2026 | [Mononucleotide interim data readout](https://sec-api.dev/pdufa/mononucleotide) | IRD |  | scheduled | "OCT, Microperimetry, Visual Acuity Status: Enrolling First participant dosed in Q4 2025 Initial data expected in Q1 2026; 3-month results from entire Cohort 1 expected in mid-2026 14 EOG, electrooculogram; OCT, Optical Coherence" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036126000913/ef20062699_ex99-1.htm)) |
| March 10, 2026 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036126008621/ef20067388_ex99-1.htm)) |
| mid-2026 | [Opus Genetics, Inc. interim data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "Initial data expected this quarter at Macula Society with 3-month results from the entire Cohort 1 expected in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036126000615/ef20062523_ex99-1.htm)) |
| May 12, 2026 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026033856/ird-2026512xex991.htm)) |
| August 6, 2026 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/ird-202686xex991.htm)) |
| Sep 2026 | [Replace topline data readout](https://sec-api.dev/pdufa/replace) | IRD |  | scheduled | "•Opus Genetics expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial in September 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026033856/ird-2026512xex991.htm)) |
| Sep 2026 | [Mononucleotide PDUFA date](https://sec-api.dev/pdufa/mononucleotide) | IRD |  | scheduled | "Study Start Q1 2027 MERTK clinical study initiation Q4 2026 RDH12 clinical study initiation Q4 2026 LCA5 Phase 3 dosing initiation Oct 2026 PDUFA date for Phentolamine sNDA Sept 2026 BEST1 Phase 1/2 Cohort 1" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036126036277/ef20081922_ex99-1.htm)) |
| Sep 2026 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/ird-202686xex991.htm)) |
| Sep 2026 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "•Enrollment was completed in Cohort 1 of the Phase 1/2 trial (BIRD-1), with 3-month topline data from Cohort 1 expected during the second week of September 2026, assuming all participants complete their assessments as scheduled." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/ird-202686xex991.htm)) |
| Q4 2026 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "Following availability of validated clinical drug supply manufactured with the intended commercial processes, Phase 3 dosing with OPGx-LCA5 is anticipated in the fourth quarter of 2026 with topline clinical data expected approximately one year later." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1228627/000162828026034084/ird-20260331.htm)) |
| October 16, 2026 | [Opus Genetics, Inc. label expansion decision](https://sec-api.dev/companies/ird/catalysts) | IRD | presbyopia in adults | completed, approved | "On October 16, 2026, the FDA approved the Company's supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia in adults." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1228627/000162828026072697/ird-20260930.htm)) |
| October 17, 2026 | [Opus Genetics, Inc. PDUFA date](https://sec-api.dev/companies/ird/catalysts) | IRD | presbyopia - | scheduled | "In February 2026, the FDA accepted the sNDA and set a Prescription Drug User Fee Act (PDUFA) action date of October 17, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1228627/000162828026054381/ird-20260630.htm)) |
| November 10, 2026 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026072493/ird-20261110xex991.htm)) |
| Q1 2027 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "•Completed enrollment and dosing of 11 participants in the high-dose Cohort 2, with topline data, including 3-month data from Cohort 2 and 6-month data for the three Cohort 1 participants with Best vitelliform macular dystrophy, expected in Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026072493/ird-20261110xex991.htm)) |
| Q2 2027 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "Cohort 2 over-enrolled, with dosing expected to be completed in Q4 2026 and topline 3-month data expected in Q2 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036126035979/ef20081753_ex99-1.htm)) |
| August 2027 | [0.75% phentolamine ophthalmic solution primary completion](https://sec-api.dev/pdufa/0-75-phentolamine) | IRD | Vision Loss Night; Vision Disorders | scheduled | "NCT07140783 (OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Opus Genetics, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07140783)) |
| Aug to Nov 2027 | [0.75% phentolamine ophthalmic solution topline data readout](https://sec-api.dev/pdufa/0-75-phentolamine) | IRD | Vision Loss Night; Vision Disorders | scheduled | "NCT07140783 (OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Opus Genetics, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07140783)) |
| late 2027 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "Topline data from the Phase 3 trial is expected by the end of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1228627/000162828026072697/ird-20260930.htm)) |
| late 2027 | [Opus Genetics, Inc. topline data readout](https://sec-api.dev/companies/ird/catalysts) | IRD |  | scheduled | "Topline data from the study is expected by the end of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000162828026053824/ird-202686xex991.htm)) |

## Drugs

- [0.75% phentolamine ophthalmic solution](https://sec-api.dev/pdufa/0-75-phentolamine): Vision Loss Night
- [APX3330](https://sec-api.dev/pdufa/apx3330): presbyopia completed enrollment, presbyopia
- [Mononucleotide](https://sec-api.dev/pdufa/mononucleotide): 
- [Replace](https://sec-api.dev/pdufa/replace): 
- [RYZUMVI (ryzumvi)](https://sec-api.dev/pdufa/ryzumvi): presbyopia in adults

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ird/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IRD catalysts: Opus Genetics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ird/catalysts

```bibtex
@misc{secapidev_companies_ird_catalysts_20261116,
  title        = {IRD catalysts: Opus Genetics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ird/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ird_catalysts_20261116","title":"IRD catalysts: Opus Genetics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ird/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
